MRE-269   Click here for help

GtoPdb Ligand ID: 5852

Synonyms: ACT 333679 | ACT-333679 | MRE 269
PDB Ligand
Compound class: Synthetic organic
Comment: MRE-269 is the active metabolite of the approved drug selexipag. MRE-269 behaves as a partial agonist in cAMP assays [3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 11
Topological polar surface area 75.55
Molecular weight 419.22
XLogP 5.3
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OC(=O)COCCCCN(c1cnc(c(n1)c1ccccc1)c1ccccc1)C(C)C
Isomeric SMILES OC(=O)COCCCCN(c1cnc(c(n1)c1ccccc1)c1ccccc1)C(C)C
InChI InChI=1S/C25H29N3O3/c1-19(2)28(15-9-10-16-31-18-23(29)30)22-17-26-24(20-11-5-3-6-12-20)25(27-22)21-13-7-4-8-14-21/h3-8,11-14,17,19H,9-10,15-16,18H2,1-2H3,(H,29,30)
InChI Key OJQMKCBWYCWFPU-UHFFFAOYSA-N
Bioactivity Comments
ADP-induced aggregation of platelets is an in vitro tool used as a surrogate for PGI2 receptor activation.
MRE-269 inhibits aggregation of human platelets with an IC50 of 200nM [1].
Selectivity at GPCRs
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
IP receptor Hs Agonist Full agonist 7.7 pKi - 2,4
pKi 7.7 (Ki 2x10-8 M) [2,4]
IP receptor Rn Agonist Full agonist 6.7 pKi - 4
pKi 6.7 (Ki 2.2x10-7 M) [4]
EP4 receptor Hs Agonist Agonist 5.3 pKi - 4
pKi 5.3 (Ki 4.9x10-6 M) [4]
EP2 receptor Hs Agonist Agonist 5.2 pKi - 4
pKi 5.2 (Ki 5.8x10-6 M) [4]